SynAct Pharma AB (OSTO:SYNACT) Short Interest


OSTO:SYNACT SynAct Pharma AB OSTO:SYNACT
18 GF Score
Price kr15.06
! 1 Warning Sign
View Full Analysis

What is SynAct Pharma AB Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

OSTO:SYNACT vs VRTX, REGN, ALNY: Short Interest Comparison

For the Biotechnology subindustry, SynAct Pharma AB's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SynAct Pharma AB Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SynAct Pharma AB's Short Interest distribution charts can be found below:

* The bar in red indicates where SynAct Pharma AB's Short Interest falls into.


OSTO:SYNACT
18GF Score
SynAct Pharma AB OSTO:SYNACT
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SynAct Pharma AB Business Description

Other Exchanges 8F8:Germany
Address Scheelevagen 2, Lund, SWE, 223 63
SynAct Pharma AB is a clinical-stage biotechnology company focused on resolving inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation-resolution activity to help patients achieve immune balance and overcome inflammation. AP1189, the company's drug candidate, is being evaluated in three Phase 2 clinical programs regarding rheumatoid arthritis, idiopathic membranous glomerulonephritis and virus-induced respiratory failure.
18GF Score

Get the complete analysis for OSTO:SYNACT

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr15.06
Price